Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jan 2007

Gallmeier Eike, Kern Scott E

Abstract excerpt

Defects in the Fanconi anemia (FA) pathway occur in subsets of diverse human cancers. The hypersensitivity of FA pathway-deficient cells to DNA interstrand cross-linking and possibly other agents renders these genes attractive targets for a genotype-based, individualized anticancer therapy. A prerequisite before clinical trials is the validation and quantification of this hypersensitivity in suitable preclinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Linking Reagents

Share to Fanconi Anemia Complementation Group Proteins

Share to Gene Expression Regulation, Neoplastic

Share to Models, Biological

Share to Neoplasms

Share to Pharmacogenetics

Source

Identifiers

PMID: 17200332
DOI: 10.1158/1078-0432.CCR-06-1637

Genes

BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.PMID 17200332Read ↗

Fanconi anemia-isogenic head and neck cancer cell line pairs - a basic and translational science resourceSemantic proximity Read ↗

Comprehensive review on Fanconi anemia: insights into DNA interstrand cross-links, repair pathways, and associated tumorsSemantic proximity Read ↗

Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy.Semantic proximity Read ↗

Exploiting the Fanconi Anemia Pathway for Targeted Anti-Cancer TherapySemantic proximity Read ↗

Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.Semantic proximity Read ↗

DNA crosslinking damage and cancer - a tale of friend and foe.Semantic proximity Read ↗

Fanconi anemia‐isogenic head and neck cancer cell line pairs: A basic and translational science resourceSemantic proximity Read ↗

Learning from a paradox: recent insights into Fanconi anaemia through studying mouse models.Semantic proximity Read ↗

DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target.Semantic proximity Read ↗

Hypomorphic Brca2 and Rad51c double mutant mice display Fanconi anemia, cancer and polygenic replication stress.Semantic proximity Read ↗

Disruption of the Fanconi anemia pathway in human cancer in the general population.Semantic proximity Read ↗

Disease model: Fanconi anemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.